Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of…
We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.
Treatment Action Group welcomes the flurry of tuberculosis (TB) data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). This statement includes a summary of major findings, TAG’s take on them, and a more detailed overview of key findings.
Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.
TAG, as part of the Save NY Public Health Campaign, called out Governor Cuomo's recently announced Medicaid cuts and other failures to adequately address health and health equity in his January 8, 2020 "State of the State" address.
TAG’s work in 2019 demonstrated our leadership towards an end to HIV, hepatitis C, and tuberculosis through hard-hitting, science-based activism. Excerpts of the media coverage we received walk you through a remarkable year of TAG’s work.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.